ライフサイエンスコーパス: alcoholic

1 ntial therapeutic target for hyperalgesia in alcoholics.

2 pe-specific genes with altered expression in alcoholics.

3 e imaging (fMRI) from 42 long-term abstinent alcoholic (25 women) and 46 nonalcoholic (24 women) part

4 uclei isolated from the prefrontal cortex of alcoholic and control individuals.

5 Those notes seem to mask alcoholic and fruit-in-syrup descriptors and the common

6 bacteria development, without affecting the alcoholic and malolactic fermentations.

7 he present study was to perform simultaneous alcoholic and malolactic wine fermentations using free o

8 ssed hepatitis B virus during treatment, and alcoholic and nonalcoholic fatty liver disease.

9 ntify genes whose expression differs between alcoholics and controls.

10 mance in apparent hydrogenolysis of etheric, alcoholic, and esteric C-O bonds to generate saturated a

11 Etiology was mostly viral and alcoholic, and there were no dropouts.

12 ured ranged from 0.41%v/v in traditional non-alcoholic beers to 0.43%v/v in sour non-alcoholic beers.

13 Sour non-alcoholic beers were brewed with the addition of juice f

14 Recipes for traditional and sour non-alcoholic beers were developed in this study employing a

15 non-alcoholic beers to 0.43%v/v in sour non-alcoholic beers.

16 Solid-state fermented Chinese alcoholic beverage (baijiu) and ethanol resulted in dist

17 tion between different types and quantity of alcoholic beverage consumption (alone and interacting wi

18 ectively assessed total alcohol and specific alcoholic beverage consumption and risk of hip fractures

19 esent results support an association between alcoholic beverage consumption and self-report severe pe

20 ng for confounding factors, the frequency of alcoholic beverage consumption was significantly higher

21 Data on type and frequency of alcoholic beverage consumption were obtained from a semi

22 Beer is one the most consumed alcoholic beverage in the world and its contamination wi

23 In women, the alcoholic beverage most significantly associated with hi

24 Honey spirit is an alcoholic beverage produced by fermentation followed by

25 to determine the amount of methanol in real alcoholic beverage samples.

26 ording to race/ethnicity, lifestyle factors, alcoholic beverage type, and anatomical subsite of tumor

27 y as well as sex, lifestyle-related factors, alcoholic beverage type, and anatomical subsite, we anal

28 s a globally produced, marketed and consumed alcoholic beverage, which is valued for its aromatic and

29 llected from individuals who had consumed an alcoholic beverage.

30 O) and as flavouring agents of two artisanal alcoholic beverages (a beer and a liqueur).

31 The results showed that all the investigated alcoholic beverages (ABs), with the exception for vodkas

32 1B and AGBL2); (ii) five loci for bitter non-alcoholic beverages (ANXA9, AHR, POR, CYP1A1/2 and CSDC2

33 oncentration was performed in 167 samples of alcoholic beverages (craft beers, soft drinks, wines, an

34 ed additional loci: (i) four loci for bitter alcoholic beverages (GCKR, KLB, ADH1B and AGBL2); (ii) f

35 found between impulsivity and consumption of alcoholic beverages and appetizers, whereas negative ass

36 associations between photographs of objects (alcoholic beverages and neutral items) and photographs o

37 ant capacity (TEAC) of each of these various alcoholic beverages is determined using an electron para

38 owever, it is assumed that the TEAC value of alcoholic beverages is independent of the alcohol conten

39 ict tax-related legal regulations concerning alcoholic beverages require precise methods for quality

40 hip fractures, few have considered specific alcoholic beverages separately.

41 Neither type nor order of consumed alcoholic beverages significantly affected hangover inte

42 glass and enameled decorations of bottles of alcoholic beverages sourced from retailers in the U.K. w

43 ied to the analysis of 12 different types of alcoholic beverages with an alcohol content ranging from

44 l alcohol consumption and intake of specific alcoholic beverages with risk of COPD in a population-ba

45 Beer has been one of the most consumed alcoholic beverages worldwide.

46 fluence on the antioxidant properties of the alcoholic beverages, were identified.

47 Alcoholic beverages, which are consumed widely in most p

48 rs (105 breath samples) after consumption of alcoholic beverages.

49 red ready-to-drink fruit juices and flavored alcoholic beverages.

50 there was no clear association with specific alcoholic beverages.

51 t juices, coffee and tea, and wine and other alcoholic beverages.

52 he chemical compositions of nonalcoholic and alcoholic beverages.

53 d acetaldehyde) was found in the majority of alcoholic beverages.

54 udy on the antioxidant properties of various alcoholic beverages: beers, wines, tinctures, and strong

55 elopment of alcoholic liver disease (ALD) in alcoholics by releasing free fatty acids and inflammator

56 Alcoholic CHG 4%-5% was ranked as the most effective ant

57 idelines worldwide which advocate the use of alcoholic CHG for preoperative skin antisepsis.

58 tic tools for staging the progression of non-alcoholic chronic liver failure from fatty liver disease

59 with cryptogenic cirrhosis (CC) (n = 6087), alcoholic cirrhosis (AC) (n = 16 810), and autoimmune he

60 , P < 0.001), "substantial" in patients with alcoholic cirrhosis (HR 1.007, P < 0.001), and "rather w

61 13; P < 0.001), substantial in patients with alcoholic cirrhosis (HR, 1.007; P < 0.001) and rather we

62 d re-LT for cryptogenic cirrhosis (n = 189), alcoholic cirrhosis (n = 300) or autoimmune hepatitis ci

63 thanol-treated mice, and human patients with alcoholic cirrhosis and healthy controls were used to qu

64 cytes/macrophages were increased compared to alcoholic cirrhosis and monocytes were found to be locat

65 Risk of alcoholic cirrhosis is determined by genetic and environ

66 ses of liver tissue from patients with AH or alcoholic cirrhosis or normal liver tissue from hepatic

67 er of early readmission, age > 64 years, non-alcoholic cirrhosis, and length of stay > 10 days were s

68 cytes/macrophages were increased compared to alcoholic cirrhosis, and monocytes were found to be loca

69 is associated with chronic viral infections, alcoholic cirrhosis, and nonalcoholic fatty liver diseas

70 ect on alcohol consumption and its weight on alcoholic cirrhosis.

71 lyses revealed blunted brain responsivity in alcoholic compared to nonalcoholic groups, as well as ge

72 ip-based systems aiming the determination of alcoholic content in whiskey samples.

73 The alcoholic content was determined in 16 seized whiskey sa

74 evels to other wine features (wine ageing or alcoholic content) were found.

75 affected wine characteristics by increasing alcoholic content, acidity, hue and phenolic substances.

76 of grape seeds allowed for the highest final alcoholic content, which was measured by HPLC, ie 120.73

77 olyphenol Index), and wines according to the alcoholic degree and TPI.

78 achines permitted to predict the TPI and the alcoholic degree of wines, from data provided by the bio

79 velop the fermentation producing ciders with alcoholic degrees between 8.75 and 11.52 (% v/v) and vol

80 ; 4) with diabetes mellitus; 5) consuming >1 alcoholic drink per week or current/former smokers; 6) w

81 itis, and who reported drinking at least one alcoholic drink per week, 1560 had a hospital admission

82 -2018 from the Portuguese Association of Non-Alcoholic Drinks (GlobalData and Nielsen Consumer Panel)

83 er day for over 20 years, consumed 3 or more alcoholic drinks per day, was a high school graduate, ha

84 very rate of Q < 0.05) between the number of alcoholic drinks per week and DNA methylation at 5,458 c

85 s (ORs) per 1-SD increase of log-transformed alcoholic drinks per week were 1.27 ([95% CI, 1.12-1.45]

86 g initiation, age of smoking initiation, and alcoholic drinks per week.

87 The clinical picture of alcoholic end-stage liver disease is rendered extremely

88 lpy by cosequestration of protons within the alcoholic environment provided by encapsulated diol-func

89 Hyperalgesia often occurs in alcoholics, especially during abstinence, yet the underl

90 Bitters are the concentrated alcoholic extract of flavorful plant materials with a wi

91 Leptin is a vital biomarker of non-alcoholic fatty liver (NAFLD), and its evaluation of the

92 rhosis (14.5%), hepatitis C (13.4%), and non-alcoholic fatty liver disease (5.7%).

93 (NHANES) data to estimate the prevalence of alcoholic fatty liver disease (AFLD) overall and with st

94 tudy, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of

95 Non-alcoholic fatty liver disease (NAFLD) affects 1 in 3 Ame

96 Non-alcoholic fatty liver disease (NAFLD) affects over 30% o

97 The prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among elderly have

98 d altered energy metabolism is common in non-alcoholic fatty liver disease (NAFLD) and appears to als

99 Sonic Hedgehog (SHH) is associated with Non-alcoholic fatty liver disease (NAFLD) and development of

100 syndrome, obesity, type II diabetes and non-alcoholic fatty liver disease (NAFLD) are increasing and

101 ease especially in diabetes mellitus and non-alcoholic fatty liver disease (NAFLD) but studies examin

102 Mitochondrial adaptation during non-alcoholic fatty liver disease (NAFLD) include remodeling

103 Non-alcoholic fatty liver disease (NAFLD) is a complex chron

104 Non-alcoholic fatty liver disease (NAFLD) is a frequent cond

105 Non-alcoholic fatty liver disease (NAFLD) is a leading cause

106 Non-alcoholic fatty liver disease (NAFLD) is a substantial c

107 Non-alcoholic fatty liver disease (NAFLD) is an emerging dis

108 people living with HIV (PLWH), of which non-alcoholic fatty liver disease (NAFLD) is an increasingly

109 Non-alcoholic fatty liver disease (NAFLD) is an obesity- and

110 Non-alcoholic fatty liver disease (NAFLD) is highly prevalen

111 The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing rapi

112 The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worl

113 the role of stress in the development of non-alcoholic fatty liver disease (NAFLD) is largely unexplo

114 Non-alcoholic fatty liver disease (NAFLD) is often associate

115 Non-alcoholic fatty liver disease (NAFLD) is the most preval

116 ed cellular lipid storage on obesity and non-alcoholic fatty liver disease (NAFLD) pathophysiology in

117 In non-alcoholic fatty liver disease (NAFLD) patients and obese

118 ith advanced liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) remains challengin

119 epatitis (NASH) is a progressive form of Non-alcoholic fatty liver disease (NAFLD), a chronic liver d

120 esis are critical for the progression of non-alcoholic fatty liver disease (NAFLD), but the underlyin

121 is decreased in human liver samples with non-alcoholic fatty liver disease (NAFLD), non-alcoholic ste

122 4) that associate with increased risk of non-alcoholic fatty liver disease (NAFLD), non-alcoholic ste

123 ic metabolic diseases including obesity, non-alcoholic fatty liver disease (NAFLD), type 2 diabetes a

124 Obesity triggers the development of non-alcoholic fatty liver disease (NAFLD), which involves al

125 rs protection against the development of non-alcoholic fatty liver disease (NAFLD).

126 erse health outcomes in humans including non-alcoholic fatty liver disease (NAFLD).

127 s, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).

128 c 12-hour clock and promotes spontaneous non-alcoholic fatty liver disease (NAFLD).

129 d with metabolic abnormalities including non-alcoholic fatty liver disease (NAFLD).

130 n (HP)-diet and/or beta-cryptoxanthin in non-alcoholic fatty liver disease (NAFLD).

131 at parallel stages in the development of non-alcoholic fatty liver disease (NAFLD).

132 r related complications in patients with non-alcoholic fatty liver disease (NAFLD).

133 ammation and fibrosis in mouse models of non-alcoholic fatty liver disease and advanced fibrosis, as

134 abetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease and autoimmune and neurode

135 and obesity are common in cirrhosis and non-alcoholic fatty liver disease has become an important ca

136 Monitoring the progression of non-alcoholic fatty liver disease is hindered by a lack of s

137 Remarkably, in non-alcoholic fatty liver disease patients, hepatic expressi

138 Non-alcoholic fatty liver disease ranges from steatosis to n

139 ucleotide variants in the progression of non-alcoholic fatty liver disease to non-alcoholic steatohep

140 buted to increasing rates of obesity and non-alcoholic fatty liver disease(2-4).

141 ients with histologically-defined NAFLD (non-alcoholic fatty liver disease) activity score (NAS) >= 4

142 Non-alcoholic fatty liver disease, characterized in part by

143 In a diet-induced mouse model of non-alcoholic fatty liver disease, the sensor achieved overa

144 These findings may also apply to non-alcoholic fatty liver disease, which shares similar path

145 cess alcohol intake, viral hepatitis and non-alcoholic fatty liver disease, with the clinical spectru

146 or progression of alcohol-associated and non-alcoholic fatty liver disease-the most common chronic li

147 lications of metabolic syndrome, such as non-alcoholic fatty liver disease.

148 diseases, including type 2 diabetes and non-alcoholic fatty liver disease.

149 icial effects that have implications for non-alcoholic fatty liver disease.

150 resistance, type 2 diabetes mellitus and non-alcoholic fatty liver disease.

151 itigate the complications of obesity and non-alcoholic fatty liver disease.

152 steatosis, a hallmark of human pediatric non-alcoholic fatty liver disease.

153 Non-alcoholic fatty-liver disease (NAFLD) is frequent in obe

154 of inoculation (sequential and simultaneous alcoholic fermentation (AF)/malolactic fermentation (MLF

155 e evolution of MND, HMND, and ketols through alcoholic fermentation and wine aging.

156 ced wine protein concentration at the end of alcoholic fermentation but heat was less efficient than

157 nd the colour and phenolics extracted during alcoholic fermentation into wines.

158 evolution of the phenolic profile during the alcoholic fermentation of white wines obtained from Fete

159 3-indoleacetic acid are produced during the alcoholic fermentation of wort.

160 Alcoholic fermentation resulted in a significant decreas

161 ve been followed during the winemaking, from alcoholic fermentation to post-fermentative maceration.

162 evaluating mitigation of nivalenol (NIV) in alcoholic fermentation with magnetic field application (

163 At the end of the alcoholic fermentation, NIV was mitigated by 56.5%.

164 During the primary alcoholic fermentation, the consumption rate of fermenta

165 in all wines increased significantly during alcoholic fermentation.

166 ratory-scale white wines was observed during alcoholic fermentation.

167 Alcoholic formulations of 4%-5% CHG seem to be safe and

168 The results showed that alcoholic groups are converted to carboxylic groups whil

169 , recent studies have highlighted that human alcoholics have an increased susceptibility to IAV infec

170 nically relevant progenitor markers in human alcoholic hepatitis (AH) and hepatocellular carcinoma (H

171 Although mortality due to acute alcoholic hepatitis (AH) correlates with Model for End-S

172 Alcoholic hepatitis (AH) is a life-threatening condition

173 Alcoholic hepatitis (AH) is a severe manifestation of al

174 We recently showed that alcoholic hepatitis (AH) is characterized by dedifferent

175 We found impaired autophagy both in ALD and alcoholic hepatitis (AH) mouse models and human livers w

176 lored the role of intrahepatic LCN2 in human alcoholic hepatitis (AH) with advanced fibrosis and port

177 All had clinically diagnosed severe alcoholic hepatitis (AH), no prior diagnosis of liver di

178 at result in endotoxemia, such as sepsis and alcoholic hepatitis (AH), often are accompanied by chole

179 atment in a cohort of 41 patients with acute alcoholic hepatitis (AH).

180 e fecal microbiome in patients with moderate alcoholic hepatitis (MAH) or severe alcoholic hepatitis

181 Severe alcoholic hepatitis (SAH) is often a progressive disease

182 moderate alcoholic hepatitis (MAH) or severe alcoholic hepatitis (SAH) was compared with healthy cont

183 rule, the patients admitted for severe acute alcoholic hepatitis are not eligible for liver transplan

184 Within the alcoholic hepatitis cohort, patients with levels of at l

185 Patients with alcoholic hepatitis had significantly higher ASCA levels

186 nts with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E.

187 Early liver transplantation for alcoholic hepatitis is a potentially life-saving treatme

188 Alcoholic hepatitis is a severe and life-threatening for

189 The role of the intestinal microbiome in alcoholic hepatitis is not established.

190 r decrease was observed in fecal SCFAs among alcoholic hepatitis patients.

191 Patient MELD score and Glasgow Alcoholic Hepatitis score (GAHS) correlated with endotox

192 Alcoholic hepatitis was associated with a distinct micro

193 the fecal microbial ecology associated with alcoholic hepatitis, (2) relate microbiome changes to di

194 aceae and Ruminococcaceae) were decreased in alcoholic hepatitis, and a similar decrease was observed

195 sponses in various liver diseases, including alcoholic hepatitis, autoimmune hepatitis, and primary b

196 In the clinical setting of severe acute alcoholic hepatitis, further studies are needed for the

197 tinal mycobiota in a cohort of patients with alcoholic hepatitis, patients with alcohol use disorder,

198 trated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated A

199 th bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic eff

200 ed with increased mortality in patients with alcoholic hepatitis.

201 eful to predict the outcome in patients with alcoholic hepatitis.

202 d with the development, but not severity, of alcoholic hepatitis.

203 or alcoholic liver diseases and severe acute alcoholic hepatitis.

204 utic approach is effective for patients with alcoholic hepatitis.

205 disease and with mortality in patients with alcoholic hepatitis.

206 okine ligand types 5 (CCL5) in patients with alcoholic hepatitis.

207 tion ex vivo in whole blood of patients with alcoholic hepatitis.

208 mes and increased mortality in patients with alcoholic hepatitis.

209 athologies, such as autoimmune hepatitis and alcoholic hepatitis.

210 Compared with non-alcoholic individuals or patients with alcohol-use disor

211 l composition and colorimetric parameters of alcoholic liqueurs prepared from rose petals were evalua

212 es suggest that Chinese baijiu (CB), a clear alcoholic liquid distilled from fermented grains, contai

213 Etiologies for liver disease included non-alcoholic liver disease (58.0%), hepatitis C (26.0%), he

214 , i.e. non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALC), and hepatitis C virus (HC

215 Alcoholic liver disease (ALD) accounts for 15%-30% of tr

216 Alcoholic liver disease (ALD) causes significant morbidi

217 In the United States, alcoholic liver disease (ALD) has recently become the le

218 erally thought to promote the development of alcoholic liver disease (ALD) in alcoholics by releasing

219 Alcoholic liver disease (ALD) is a major cause of liver-

220 Alcoholic liver disease (ALD) is a significant health ha

221 consumption may modulate 5hmC formation and alcoholic liver disease (ALD) progression.

222 Alcoholic liver disease (ALD) samples were used to confi

223 s-species comparison was performed using the alcoholic liver disease (ALD) transcriptomic public data

224 trahepatic complications of viral hepatitis, alcoholic liver disease (ALD), and nonalcoholic fatty li

225 to steatosis, inflammation, and fibrosis in alcoholic liver disease (ALD).

226 aintained through autophagy, is disrupted in alcoholic liver disease (ALD).

227 factor for all liver diseases, particularly alcoholic liver disease (ALD).

228 4; 95% confidence interval [CI], 1.01-1.08), alcoholic liver disease (HR, 1.66; 95% CI, 1.02-2.71), a

229 d homeostasis during the pathogenesis of non-alcoholic liver disease (NAFLD).

230 at has been implicated in the progression of alcoholic liver disease and liver fibrosis.

231 d beige fat through cold exposure suppressed alcoholic liver disease development.

232 ys expressed in DR and genes associated with alcoholic liver disease progression.

233 Alcoholic liver disease was the main cause of liver dise

234 hol-related liver disease (previously termed alcoholic liver disease).

235 Chief among these is alcoholic liver disease, and heavy use is detrimental ir

236 cated in the pathogenesis of renal fibrosis, alcoholic liver disease, non-alcoholic steatohepatitis,

237 atients with primary sclerosing cholangitis, alcoholic liver disease, or nonalcoholic steatohepatitis

238 or C virus infection, autoimmune hepatitis, alcoholic liver disease, or without these diseases (cont

239 titis B or C virus, autoimmune hepatitis, or alcoholic liver disease, we detected increased nuclear t

240 r each model, not shared with advanced human alcoholic liver disease.

241 viral hepatitis (n=19) or other chronic non-alcoholic liver diseases (NALD) (n=27).

242 e the candidate to liver transplantation for alcoholic liver diseases and severe acute alcoholic hepa

243 Despite the growing global burden of alcoholic liver diseases, therapeutic options are limite

244 s of patients is recognized as a hallmark of alcoholic liver diseases.

245 nsumption are frequently used to investigate alcoholic liver injury and define new therapeutic target

246 ficant pathophysiological diversity of human alcoholic liver injury.

247 The release rate in the hydro-alcoholic media was linearly proportional to the swellin

248 Brain activation in alcoholic men (ALC(M)) was significantly lower than in n

249 For that, different hydro-alcoholic mixtures (50-100% ethanol content) were used t

250 id ratio (R(S-L)) and type of solvent (hydro-alcoholic mixtures) was also studied.

251 Alcoholic myopathy is more prevalent than all inherited

252 abditis elegans exhibits the key features of alcoholic myopathy when exposed to ethanol.

253 In skeletal muscle, ethanol causes alcoholic myopathy, which is characterized by myofiber a

254 taldehyde has been implicated in the painful alcoholic neuropathy, the mechanism by which the ethanol

255 Z-1,5-octadien-3-one for fruit-in-syrup and alcoholic notes.

256 em to be safe and twice as effective as PVI (alcoholic or aqueous solutions) in preventing infection

257 , when is surreptitiously administered to an alcoholic or soft drink, is associated with "drug-facili

258 cts of reducing locomotion and intake of non-alcoholic palatable solutions, whereas intranasal oxytoc

259 C-MS quantification of volatile compounds in alcoholic products was applied to 36 samples including c

260 ron-rich aromatic rings slow exchange of the alcoholic proton, thereby revealing coupling with the ge

261 confidence interval 0.24, 1.02)] and also to alcoholic PVI, although uncertainty was larger [RR 0.51

262 Cachaca is a sugarcane-derived alcoholic spirit exclusively produced in Brazil.

263 e applied for anti-counterfeiting of various alcoholic spirits by comparing the decoloration time of

264 of at least 25 kg/m(2), biopsy-confirmed non-alcoholic steatohepatitis (fibrosis stage 1-3), and a he

265 isk of developing type 2 diabetes (T2D), non-alcoholic steatohepatitis (NASH) and a host of other com

266 sis can progress to advanced stages with non-alcoholic steatohepatitis (NASH) and fibrosis, increasin

267 erging disease, where it can progress to non-alcoholic steatohepatitis (NASH) and lead to liver cirrh

268 arkedly increased in human patients with non-alcoholic steatohepatitis (NASH) and significant liver f

269 ese patients and regularly progresses to non-alcoholic steatohepatitis (NASH) and subsequent cirrhosi

270 Animal models of non-alcoholic steatohepatitis (NASH) are important tools in

271 Pharmacological treatments for non-alcoholic steatohepatitis (NASH) are still unsatisfactor

272 iver-related death) or advanced fibrosis/non-alcoholic steatohepatitis (NASH) in adult individuals wi

273 Non-alcoholic steatohepatitis (NASH) is a common type of chr

274 Non-alcoholic steatohepatitis (NASH) is a progressive form o

275 Non-alcoholic steatohepatitis (NASH) is characterised by hep

276 Non-alcoholic steatohepatitis (NASH) is major health burden

277 ded patients of NAFLD including NAFL and non-alcoholic steatohepatitis (NASH) were analyzed.

278 n-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcohol-related cirrho

279 noma (HCC) in different etiologies, i.e. non-alcoholic steatohepatitis (NASH), alcoholic liver diseas

280 on-Controlled J protein) as a target for non-alcoholic steatohepatitis (NASH), an advanced phase of N

281 n-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or cirrhosis that was

282 y liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressin

283 hepatic macrophages during diet-induced non-alcoholic steatohepatitis (NASH).

284 ted in liver biopsies from patients with non-alcoholic steatohepatitis (NASH).

285 liver disease (NAFLD) and development of Non-alcoholic steatohepatitis (NASH).

286 lerates the progression of NAFLD towards non-alcoholic steatohepatitis (NASH).

287 advanced fibrosis, as well as to detect non-alcoholic steatohepatitis and cirrhosis in biopsied samp

288 of non-alcoholic fatty liver disease to non-alcoholic steatohepatitis and fibrosis (NASH-fibrosis),

289 ise because of the growing prevalence of non-alcoholic steatohepatitis as a transplant indication and

290 6, 184 overweight or obese patients with non-alcoholic steatohepatitis were screened for study inclus

291 erous common diseases such as cirrhosis, non-alcoholic steatohepatitis, chronic renal disease, heart

292 d features of the metabolic syndrome and non-alcoholic steatohepatitis, despite its irrelevant calori

293 renal fibrosis, alcoholic liver disease, non-alcoholic steatohepatitis, pulmonary fibrosis and cancer

294 d in the pathophysiology of nonalcoholic and alcoholic steatohepatitis.

295 gbelfermin is warranted in patients with non-alcoholic steatohepatitis.

296 ed hepatic fat fraction in patients with non-alcoholic steatohepatitis.

297 ients with severe AH and in a mouse model of alcoholic steatohepatitis.

298 The pH, alcoholic strength, methanol content, acetaldehyde conte

299 strate distinct responses to the four tested alcoholic vapors (ethanol, methanol, propanol, and isopr

300 tal cortex, whereas activation was higher in alcoholic women (ALC(W)) than in nonalcoholic women (NC(